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Abstract  
 
  The development of cancer treatment were initiated by the existence of human’s effort 
to treat by applying certain materials which is mostly part(s) or extracts of plants, which are 
now adapted as traditional herbal medicine. The discovery of new drugs was based on intuition 
and empirical evidence. Thus, high luck factor was involved in a successful treatment with 
unguaranteed reproducibility. One example of drug being developed through conventional drug 
development is Taxol. Taxol is an extremely complex natural product and requires a bunch of 
hard work with high level of serendipity to be discovered as antitumor agent. Recently, rapid 
development in human biology and technology allow a change in drug discovery strategy by 
minimizing the luck factor. Targeted therapy has been a very promising strategy of drug 
development research, especially in cancer treatment. Although cancer has been known as a 
disease with very complex cellular and histo-pathophysiology, the abundance of studies on 
proteins, such as receptors and hormones, as the hallmarks of cancer allows us to explore 
carcinogenesis suppression further based on molecular targeted therapy. Kinases, one type of 
protein involved in signal transduction regulating cell growth and differentiation, could be the 
proteins that are proposed to be inhibited in suppressing tumor growth. An interesting example 
of the drug being discovered based on molecular modeling is the discovery of lapatinib as anti-
cancer with specific target on HER-2 and EGFR to overcome the resistance of cancer to 
Herceptin caused by elevated level of EGFR expression.  
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INTRODUCTION 
 
Cancer is a disease with a molecular cause 
of which vary according to each type. An 
alternative therapeutic target is the inhibition of 
proteins involved in signaling processes leading to 
the growth and development of cancer cells and the 
proteins involved in the resistance mechanisms of 
cancer. Systemic chemotherapy on cancer shows 
less effectiveness and selectiveness. It has toxic 
effects on normal cells, too. 
Breast cancer, a sample of major death 
cause, is the most common cause of cancer death 
in several decades. The molecular mechanism of 
breast cancer is not fully understood, but it is 
possibly related to the expression of oncogenes 
such as c-myc, ERBB2, and Ras (Bouker et al., 
2005). Breast cancer is also caused by mutations of 
BRCA1 (breast cancer, type 1), BRCA2 (breast 
cancer, type 2), and p53 gene (Kumar et al., 2000). 
The other possible mechanism is the inactivation of 
p53 wild-type resulting in the loss of function as a 
tumor suppressor gene (Hanahan and Weinberg et 
al., 2011). The failure of breast cancer therapies 
are mostly caused by resistance or multidrug 
resistance. This phenomenon is mediated by breast 
cancer resistance protein (BCRP), such as P-
glycoprotein (Pgp) (Imai et al., 2004). Thus, 
developing a specific drug for resistant breast 
cancer therapy to reduce death of breast cancer 
patients is such an urgent issue. 
Conventional drug discovery began with 
virtually the same methods belong to the early 
antibiotics. Bioassays were used to screen large 
libraries of natural products, phytochemicals, or 
synthetic organic compounds to find a few 
bioactive chemicals. 
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We could barely find compounds derived 
from screening to be directly useful as anticancer 
drugs. The candidate must be elaborated to a drug 
through repetitive synthesis of chemical analogs to 
improve its specificity, potency, bioavailability, 
and safety. Many years needed to elaborate a 
screening drug candidate into a preclinical drug 
development candidate.  
Nevertheless, most candidates failed to be 
synthesized in an acceptable amount and 
accurately predict key aspects of drug behavior in 
human clinical trials. As a result of the high failure, 
the cost of drug development is getting higher and 
reach $10 million budget per drug item 
(Matsumoto, 2008).  
The cancer therapy has been switched to 
molecular targeted therapy that is based on protein 
library and chemical library (synthetic and 
phytochemicals) (Lee et al., 2011). Molecular 
targeted therapy ensures more effectiveness and 
efficiency since only tumor cells, not the normal 
cells would be affected. Specific drug for 
molecular targeted therapy discovery is important 
to be the focus of cancer drug development. And 
the resistance being involved in molecular targeted 
therapy would be also a focus in order to overcome 
resistance problem.  
 
Conventional Drug Development 
Indonesia, as one of "megabiodiversity" 
countries of the world, possesses a huge number of 
bio-resources which can be applied to a wide range 
of natural products, such as herbal/traditional 
medicine for cancer therapy as both as first-line 
drug of therapy and as complementary drug of 
conventional chemotherapeutic agents in 
combinational therapies. Drug development in 
Indonesia started with the applications of 
traditional medicine. Currently, both natural 
products chemists and phytochemists believes that 
the secondary metabolites contained in natural 
products are mostly used in the purpose of mostly 
self defense against harmful effects of toxins, 
carcinogens, or mutagens found in the plant 
(Mitscher et al., 1986) or attack by external 
predators (Woodbury et al., 1961). 
Pharmacological tests was done to proof their 
activity, starting from collection of samples, 
extraction, bioassay, pre-clinical study, 
formulation, until finally clinical trials are 
conducted. 
 One example of drug being developed 
through conventional drug development is Taxol. 
Having the mechanism of antitumor activity 
through binding to a protein, tubulin, causing the 
inhibition of cell division, taxol has been called as 
the best new anticancer agent being developed 
from natural products, showing efficacy against 
ovarian cancer (Wall and Wani, 1996), even being 
referred as ‘the most important new drug we have 
had in cancer in 15 years by NCI (Kolata, 1991). 
Taxol is an extremely complex natural product, 
possessing the molecular weight of 853, forming 
the compound C47H51NO14 (Fig. 1) (Wani et al., 
1971). Just like many previous investigations of 
biocompounds’ activity, the discovery of this 
antitumor agent requires a bunch of hard work with 
high level of serendipity (Wall and Wani, 1996). In 
the early 1960s, as part of the NCI–United States 
Department of Agriculture (hereafter USDA) plant 
screening program, taxol was found to be present 
in the bark of the Pacific yew (Taxus brevifolia), a 
slow growing tree mainly in the Pacific Northwest 
of the United States, in Oregon and Washington. 
Their development into clinically active agents 
lasted for about 30 years, from the early 1960s to 
the 1990s (Fig.2) (Cragg and Newman, 2005). 
 
 
 
 
 
 
 
 
Figure 1. Structure of Taxol 
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1962: Bark was first collected 
 
 
1964: Extract observed to be cytotoxic on several types of cancer cells 
 
 
1977: Study on mechanism of action began 
 
 
1989: First clinical trial reported 
 
 
1992: Approved for treatment of refractory ovarian cancer by FDA 
 
 
1994: Approved for second-line treatment of metastatic breast cancer by FDA 
 
Figure 2. Development of Taxol as chemotherapeutic agent 
 
The bark was first collected in 1962, then 
the extract was found to be strongly cytotoxic 
against several types of cancer cells two years later 
(Walsh and Goodman, 1999). The study of the 
mechanism of action of this molecule was initiated 
in 1977 (Horwitz, 2004), and taxol bioactivity was 
then demonstrated at first in 1979, and the first 
results of clinical trials were reported a decade 
later, followed by the announcement of taxol’s 
potential in the treatment of ovarian cancer to the 
public (Suffness, 1994). FDA approved taxol as an 
effective chemotherapeutic agent against a wide 
range of tumor in 1992 (Kohler and Goldspiel, 
1994). In 1998, taxol was approved for use against 
ovarian and advanced breast cancer in many parts 
of the world, even has been the first-line drug of 
choice in ovarian cancer treatment; and is potential 
to be used against other types of cancer. 
Nowadays, taxol is widely used in about one fourth 
of cancer treatment incidence. 
Following the announcement of taxol’s 
potential as anticancer agent, controversies came 
along. The issue of developing cancer 
chemotherapy versus the issue of environmental 
protection came up, since stripping the bark from 
the yew killed the tree (Walsh and Goodman, 
1999). Between 1974 and 1989, NCI had extracted 
bark from about 7500 trees (Snader, 1990) mostly 
for investigative research. After 1984, when taxol 
entered phase I clinical trials, the order increased 
gradually. Until at least the end of 20
th
 century, this 
tree was still the main source of the molecule 
(Walsh and Goodman, 1999), with the yield of 
only about 0.004%, since approximately 0.5 g of 
taxol isolated requires around 12 kg of air-dried 
stem and bark (Wall and Wani, 1996). While a full 
course of treatment for a patient may require 2 g of 
taxol, being administrated several times over many 
months (Strobel et al., 1996). Rendering to those 
facts, the synthesis of taxol was then developed. 
Although it was around the end of the 20
th
 
century when the semisynthetic method 
(conversion of baccatin III or 10-deacetylbaccatin 
III) obtained from Taxus spp. to taxol) (Stierle et 
al., 1994; Denis et al., 1988) and total synthesis 
was introduced (Nicolau et al., 1994), problem 
remained, since those multistep processes seemed 
uneconomical. In order to lower the price of taxol, 
fermentation process was then developed. The 
discovery of Taxomyces andreanae (organism 
other than Taxus spp. being able to produce taxol) 
was the first to be demonstrated (Stierle et al., 
1994). Unfortunately, the yields of taxol and 
taxanes obtained was low. Research on the 
development of synthesis and biosynthesis 
technique in obtaining taxol is recently still 
ongoing to develop more effective routes to this 
biocompound, together with the investigation of 
more biologically active and easier to synthesize 
molecule derived from the molecule (Guo et al., 
2006). Furthermore, biotechnological approach 
was also conducted, in order to establish highly 
productive cell cultures at the industrial level 
(Exposito et al., 2009). 
The review above shows that the 
development of anticancer drug which is based on 
the natural materials led to a serendipitous and 
exhausting research, spanning over a long period 
of time. Thus, anticancer drug development 
paradigm which is based on the exploration of 
natural materials led to the slow development of 
cancer drug discovery in Indonesia. However, 
previous studies on natural products brings along 
huge amount of information allowing a rapid 
development of it through translational researches 
on targeted therapy, which is promising. Besides, 
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further exploration may also provide scientific 
basis and targeted therapy approach for the 
application of natural products that are still widely 
used, particularly on cancer treatment, both solely 
and in combination with established 
chemotherapeutic agents. 
 
Translational Drug Development 
Translational research is a concept of 
research with a shortcut that may shorten the path 
of new drug discovery. With the basis of 
bioinformatics-genomics and the abundant 
information on molecular targeting of pathogenesis 
biomarker, we may computationally design a 
molecule predicted to be potentially active and 
easily synthesized. This model may predict a 
molecule as potent candidate from genotypic level 
to then brought into phenotypic level (Fig. 3). 
 
 
 
 
 
Figure 3. Basic concept of translational research, by analyzing interactions in genotypic level to predict 
phenomenon in phenotypic level, giving the chance to skip several high-failure-risky steps of drug 
development. 
 
Identification of the protein markers in a 
specific cancer is essential for developing chemical 
library of molecules that are potential to have 
specific interactions on them. The specific 
interaction of receptor and its ligands is expected 
to modulate the normal effect of the protein. This 
model of interaction ensures more effectiveness of 
the agent when administrated solely and may 
decrease the side effect caused by 
chemotherapeutic agents when applied in 
combination. This strategy is effectively supported 
by the increasing techniques in drug discovery 
based on molecular modeling employing computer 
modeling based drug design. An interesting 
example of the drug being discovered based on 
molecular modeling is the discovery of lapatinib as 
anti-cancer with specific target on HER-2 and 
EGFR to overcome the resistance of cancer to 
Herceptin (Konecny et al., 2008). 
HER-2, or HER-2/neu or Erb-B2 receptor, is 
a member of the EGFR superfamily, a tyrosine 
kinases transmembrane receptor. This growth 
factor receptor influences the growth, survival, 
metastasis, invasiveness, and angiogenesis of 
tumor cells (Laskin et al., 2004). Since HER-2 is 
expressed as the hallmark of several cases of 
malignant breast cancer, such receptor has been a 
promising target in breast cancer. Thus, HER-2 
becomes the important target in the inhibition of 
cell proliferation. One drug that is popularly used 
which targets HER-2 receptor is Herceptin. 
Herceptin is clinically effective for breast 
cancer with HER2 over expression, but breast 
cancer patients develop resistance in prolonged 
used, caused by elevated level of EGFR 
expression. Therefore, EGFR is an important target 
in breast cancer drug development. Gefitinib (Fig. 
4) is a small molecule given orally and works by 
blocking the mechanism of EGFR at the ATP 
binding site, thereby inhibiting proliferation, 
differentiation, and angiogenesis (Birnbaun et al., 
2005). On the other hand, gefitinib causes 
resistance and secondary mutation (Yang et al., 
2005). To overcome the secondary mutation 
caused by gefitinib, one has developed WZ4002, a 
compound that targets EGFR without causing other 
resistance mechanism. WZ4002 is selective to 
mutated EGFR with no effect on wild type EGFR 
      In vivo 
In vitro 
(target 
validation) 
Basic Researches 
Clinical trials 
 Bioinformatics-Genomic 
Molecular target-biomarker 
Clinical-basic research 
Clinical use 
(market) 
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(Zhou et al., 2009). Therefore, unless some efforts 
are taken to overcome the phenomenon, there 
would be no effective treatment to breast cancer 
remains. 
 
 
 
Figure 4. Chemical structure of Gefitinib 
 
EGFR family has four members that their 
binding with proper ligands lead to the activation 
of signaling cascades involved in cell proliferation 
and survival (Nahta et al., 2003; Moy and Gross, 
2006). Although ligands for HER-2 are not known, 
it plays a role in EGFR-family signaling through 
heterodimerization with other members of the 
family (Rusnak et al., 2001). Since the 
overexpression of EFGR and HER-2 are the 
hallmarks of some cases of breast cancer, agents 
inhibiting both EGFR and HER2 might be more 
effective against cancer than those targeting either 
receptor alone. This idea led to the development of 
lapatinib (Moy et al., 2007). 
Lapatinib (Fig. 5) is a tyrosine kinase 
inhibitor that works on both EGFR and HER2 
tyrosine kinase domains (Fig. 6) (Moy and Goss, 
2006; Rusnak et al., 2001; Konecny et al., 2006). 
Not only showed potent activity against cancers 
with overexpression of EGFR and HER2, the drug 
is active against cell lines that are resistant to 
herceptin, thus promising in patients with 
trastuzumab-resistant cancers. Besides, since 
lapatinib is a small molecule that is able to 
penetrate the blood brain barrier, it may also 
overcome the problem of herceptin’s disability to 
treat or prevent brain metastases that develop in 
about one-third of patients with HER2 –
overexpressing metastatic breast cancer (Moy and 
Goss, 2006; Clayton et al., 2004). 
 
 
  
 
(a) 
 
(b) 
Figure 5. Chemical structure of Lapatinib (a) and its docking with EGFR (Wood et al., 2004) (b) 
 
Structural biology of protein kinase has 
given detail insights into catalytic domain of 
kinases to develop selective kinase inhibitor 
(Cowan-Jacob et al., 2009). Crystal structure of 
protein explain us binding affinity between kinase 
inhibitor and receptor. Some computational models 
have been developed and seem to be useful for 
ligand scening, ligand docking, and ligand activity 
profiling studies. Resistance of kinase domain 
because of mutation contribute to stability of 
conformation of kinase. By knowing structural 
biology of kinase, kinase inhibitor may be 
designed to overcome the resistance problems. 
According to those facts, we may see the success 
and ongoing rapid discoveries with the paradigm of 
translational research. 
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(a) 
 
(c) 
 
(b) 
 
Figure 6. Illustrations of interactions between herceptin and its receptor (a), gefitinib and its receptor (b), 
and lapatinib possessing triple receptor as targets, along with the downstream proteins involved 
(c) 
Tyrosine kinase inhibitor is one promising 
approach in developing drug for cancer targeted 
therapy, since kinases do the protein 
phosphorylation, thus play an important role in 
regulating signal transductions involved in 
proliferation, differentiation, migration, and 
apoptosis of cells. In some types of cancer, 
mutation or overexpression of certain tyrosine 
kinases occur (Broekman et al., 2011). Lapatinib is 
a tyrosine kinase inhibitor that works on both 
EGFR and HER2, two receptors that are 
overexpressed in some cases of cancer (Moy and 
Goss, 2006; Rusnak et al., 2001; Konecny et al., 
2006). Studies showed that the growth of tumor 
cells expressing those receptors are inhibited by 
lapatinib both in vitro and in vivo (Johnston and 
Leary, 2006). While leflunomide, a soluble small 
molecule tyrosine kinase inhibitor, reduced 
tyrosine phosphorylation of JAK3 and STAT6 in B 
cells (Siemasko et al., 1998). Besides, leflunomide 
also could inhibit MAP kinase activity (Rebbaa et 
al., 1996).  
Another tyrosine kinase inhibitor, sutent, 
inhibited tumor growth, metastasis, angiogenesis, 
and cell proliferation in a mouse model of 
mammary cancer (Tanaka et al., 2011). Sutent, 
which is also known as sunitinib, targets stem-cell 
factor receptor (KIT or SCFR) and FMS-like 
tyrosin kinase-3 (FLT3) that are involved in pro-
oncogenic pathway and also VEGFR and PDGFR 
that are known to play a role in angiogenesis signal 
transduction (Christensen, 2007; Nishioka et al., 
2009). 
The steroid hormone estrogen plays an 
important role in the development and 
differentiation of breast and endometrial cells, thus 
may have certain effects in the growth of cancer, 
either directly by activating oncogenic pathways or 
indirectly via mitogenic stimulus (Glaeser et al., 
2006). However, estrogen also plays an important 
role in maintaining bone density, cholesterol level, 
and reproductive tissues (Jordan, 2004). Those 
effects are mediated by specific receptor that is 
estrogen receptor (ER). Hence, ER targeting is one 
approach of both chemoprevention and cancer 
targeted therapy (Manni et al., 2011). Tamoxifene, 
a triphenylethylene, is a selective estrogen receptor 
modulator (SERM) which is able to inhibit 
estrogen binding to ER and possess both estrogen 
agonist activity in some tissues and antagonist 
activity in others (Muchmore, 2000; Osborne, 
1998; Sato et al., 1996). Subsequently, G1 phase of 
cell cycle arrest occurs (Osborne, 1998). It was 
proven to downregulate endometrial ER (Perez-
Lopez and Comenge, 1993). Tamoxifen also 
possesses agonist activity in certain tissues, thus 
categorized as SERM (Muchmore, 2000). 
Raloxifene possesses estrogen agonist activity in 
bone and lipids, and antagonist activity in breast 
and uterus (Khovindhunkit and Shoback, 1999; 
Muchmore, 2000). This nonsteroidal 
benzothiphene inhibits human uterine leiomyoma 
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HERCEPTIN 
 
 
  
EGFR 
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cells by increasing Bcl-2 protein expression 
inducing apoptosis in low concentration and 
promote their growth in high concentration in vitro 
(Buelke-Sam et al., 1998; Liu et al., 2006).  
Raloxifene that is a ERβ agonist suppressed 
proliferation and increased apoptosis of AOM-
induced colon tumor (Rao et al., 2006). Both 
compounds mentioned above are classified as 
SERMs since both estrogen agonist and antagonist 
activity have been observed, whilst fulvestrant, a 
commonly used adjuvant in breast cancer therapy, 
is an ER pure antagonist without known agonist 
effect (Jones, 2003; Osborne et al., 2004). 
Possessing distinctive different chemical structure 
compared to SERMs, this 7α-alkylsulphyl 
analogue of estrogen binds ER much stronger than 
tamoxifen does (Wakeling and Bowler, 1987 cit. 
Osborne et al., 2004; Wakeling et al., 1991 cit. 
Osborne et al., 2004). Fulvestrant inhibit ER 
signaling by blocking and accelerating the 
degradation of ER (Osborne et al., 1994). 
 
Table I. Molecular Targeted Anticancer 
 
Compound Molecular structure Activity Ref. 
Tyrosine Kinase Inhibitor 
Lapatinib 
 
Inhibits EGFR and HER2 Moy and Goss, 2006 
Rusnak et al., 2001 
Konecny et al., 2006 
Leflunomide 
 
Inhibits MAPK activity Rebbaa et al., 1996 
Sutent 
 
Inhibits SCFR, FLT3, 
VEGFR, PDGFR 
Christensen, 2007 
Nishioka et al., 2009 
Anti-estrogen and Selective Estrogen Receptor Modulator 
Tamoxifen 
 
Estrogen agonist and 
antagonist 
Muchmore, 2000 
Osborne, 1998 
Raloxifene 
 
Estrogen agonist and 
antagonist 
Khovindhunkit and 
Shoback, 1999 
Muchmore, 2000 
Fulvestrant 
 
Anti-estrogen Jones, 2003 
Tubulin binding 
Paclitaxel 
 
Promotes tubulin 
polymerization 
Saijo et al., 1996; 
Kingston, 2009 
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Vincristine 
 
Inhibits tubulin 
polymerization 
Renzulli et al., 2006 
Epothilones 
 
Promotes tubulin 
polymerization 
Borzilleri and Vite, 
2002 
COX-2 inhibitor 
Celecoxib 
 
Inhibits the activity of COX-2 Fu et al., 2004 
Liu et al., 2009   
Gao et al., 2010 
Sulindac 
 
Inhibits the activity of COX-2 Fu et al., 2004 
 
Nimesulide 
 
Inhibits the activity of COX-2 Hida et al.,2006 
CDK inhibitor 
Roscovitine 
 
Inhibits the activity of CDK1, 
CDK2, CDK5 and CDK7. 
Hajduch et al., 1999 
Sielecki et al., 2000 
 
Flavopiridol 
 
Inhibits the activity of CDK1, 
CDK2, CDK4 
Carlson et al., 1996 
Motwani et al.,2003 
Ibulocydine 
 
Inhibits the activity of CDK7 
and CDK9 
Cho et al., 2011 
BS-181 
 
Inhibits the activity of CDK7 Ali et al., 2009 
Protease Inhibitor 
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Nelfinavir 
 
Inhibits the activity of 
proteases 
Gills et al., 2007 
  
There are two anticancer mechanism of 
actions involving tubulin that are by promoting or 
by inhibiting tubulin polymerization. Tubulin itself 
is a protein assemblies and disassemblies in cell 
replication, thus any interference to it will lead to 
cell division disruption (mitotic block) and cell 
death (apoptosis) (Jordan and Wilson, 2004; 
Kingston, 2009). Paclitaxel, belongs to the taxanes, 
binds both to an N-terminal unit of β-tubulin and to 
the region bounded by AA 217-231 and promotes 
tubulin polymerization, leading to a stabilization 
that interferes microtubule dynamic instability 
(Bhalla, 2003; Rao et al., 1994 cit. Kingston, 2009; 
Rao et al., 1995 cit. Kingston, 2009; Saijo et al., 
1996). Paclitaxel is the very first taxanes being 
approved for clinical use in cancer treatment. 
Besides, this molecule also binds to Bcl-2 protein, 
thus inducing apoptosis (Sinha et al., 2011). Whilst 
vincristine, belonging to the group of vinca 
alkaloids, exhibits antimitotic activity by inhibiting 
microtubule assembly (Renzulli et al., 2006).  
Epothilones, molecules built of epoxide, 
thiazole, and ketone groups, act as anticancer 
agents with the same mechanism of action as 
paclitaxel (Borzilleri and Vite, 2002). Epothilones 
was observed to inhibit growth of cells and to be 
able to overcome resistance due to P-gp 
overexpression and specific β-tubulin mutations 
(Chou et al., 2001 cit. Borzilleri and Vite, 2002; Su 
et al., 1997 cit. Borzilleri and Vite, 2002). Not only 
possessing great antiproliferative activity in vitro, 
this group of molecules induces cell death in 
paclitaxel-resistant tumor cells in much lower 
concentration compared to paclitaxel (Carlomagno 
et al., 2003). 
Cyclooxygenase-2 (COX-2) is important 
enzyme in imflammation and carcinogenesis. 
Expression of COX-2 stimulates the occurrence of 
cancer by increasing prostanoid production that 
increases cancer cell proliferation (Kinoshita et al., 
1999). Upregulation of COX-2 causes upregulation 
of Bcl-2 that leads to apoptosis resistancy (Sheng 
et al., 1998) and causes excessive accumulation of 
prostaglandins (PGH2) which catalyzes the 
conversion of procarcinogen to be carcinogen 
(Palozza et al., 2004). Inhibition of COX-2 may 
help treat and prevent cancer.  
COX-2 inhibitors are currently being 
studied in some cancers such as breast cancer
 
and 
colon cancer treatment. Anticancer activity of 
celecoxib on gastric cancer cells is mediated by 
cell-cycle arrest and apoptosis, and not by COX-2 
or PGE2 suppression alone (Cho et al.,2007). 
Anticancer activity of celecoxib is COX-2-
independent in HT-29 and PC-3 cells (Gao et al., 
2010). Celecoxib inhibits gastric carcinoma cells 
via cyclooxygenase-2-dependent pathway by 
decreasing Bcl-2, and cyclooxygenase-2-
independent pathway by increasing p21 and p27 
(Liu et al., 2009).  Celecoxib and sulindac induce 
apoptosis, suppress proliferation and reduce 
angiogenesis and weaken invasiveness of gastric 
cancer cells (Fu et al., 2004). The other COX-2 
inhibitor anticancer drug is nimesulide. COX-2 
expression in NSCLC cells may affect their 
responsiveness to COX-2 inhibitors, so the 
apoptosis induction of nimesulide on non-small 
cell lung cancer cell is correlated to inhibition of 
COX-2 expression (Hida et al., 2006). 
Cell cycle is regulated by cyclin-dependent 
kinases (CDK), which are activated during the cell 
moves from G1 to S phase into G2 and M phases, 
which form a complex with cyclin. CDK activity is 
controlled by cell cycle inhibitor proteins known as 
CDK inhibitors (CKI). Development of CDK 
inhibitors as anticancer agents has been interesting 
topic. Roscovitine is a potent but reversible 
inhibitor of CDK1, CDk2, CDK5 and CDK7 by 
acting as a competitor of ATP binding (Hajduch et 
al., 1999; Sielecki et al.,2000). Flavopiridol has 
been shown to induce cell cycle arrest and 
apoptosis in various tumor cells in vitro and in 
vivo. Flavopiridol induces cell cycle arrest in G1 
phase by inhibition of CDK4 and/or CDK2 kinase 
activity (Carlson et al., 1996). Flavopiridol inhibits 
activity of cyclin B1/CDK1 kinase on MKN-74 
human gastric cells (Motwani et al., 2003). 
Ibulocydine (an isobutyrate prodrug of the specific 
Cdk inhibitor, BMK-Y101), a candidate anti-
cancer drug for HCC, inhibits HCC cells 
proliferation and induces apoptosis by inhibiting 
CDK7 and CDK9 (Cho et al., 2011). BS-181 is a 
synthetic compound developed based on 
computational drug development. BS-181 shows 
strong CDK inhibition activity especially CDK7, 
induces cell cycle arrest and apoptosis of cancer 
cells, and shows in vivo antitumor activity (Ali et 
al., 2009).  
Protease inhibitors perturb replication of 
HIV (human immunodeficiency virus) and 
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interfere with the protease enzyme. Blocking of 
protease leads to abberation of the new copies of 
HIV formation. Nelfinavir is one HIV protease 
inhibitor that is developed as anticancer. 
Development of nelfinavir as anticancer is directed 
by toxic effect of nelfinavir associated to inhibition 
of Akt. Nelfinavir induces cell death by caspase 
dependent and independent pahtway, decreases the 
viability of drug-resistant breast cancer cell lines 
and inhibits NSCLC xenografts growth that is 
associated with induction of ER stress, autophagy, 
and apoptosis (Gills et al., 2007).  
The abundance of information on the 
activity and molecular targets of phytochemicals 
particularly in the treatment of cancer, supported 
by studies on receptors being involved in 
carcinogenesis allows a promising translational 
research with the basis of cancer targeted therapy. 
Computational study resulting prediction of new 
active molecules may bring along an effective and 
efficient discovery and development of new drugs 
possessing anticancer activity. Besides, further and 
comprehensive studies on targeted therapy let us 
conduct a molecular approach in finding the 
scientific basis of natural products application (as 
traditional medicine). The focus of drug 
development in Indonesia should be immediately 
turned, from the development of herbal products to 
the development of modern medicine. 
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